We needed to consider two potential problems: (1) if the drug that is conjugated or bound to HSA is weak, the drug will be released from the HSA carrier into the bloodstream, leading to unexpected side effects in vivo; and (2) if the drug that is conjugated or bound to HSA is tight, the drug will not be released from the HSA carrier into the cancer cells. The gene discussed is ALB; the disease is cancer.